Description
Crinecerfont is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in people four years of age and older with classic congenital adrenal hyperplasia.
The most common side effects of crinecerfont in adults include fatigue, dizziness, and arthralgia (joint pain). For children, the most common side effects include headache, abdominal pain, and fatigue.
Crinecerfont was approved for medical use in the United States in December 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
CRENESSITY™ (crinecerfont) capsules, for oral use
CRENESSITY™ (crinecerfont) oral solution Initial U.S. Approval: 2024
See full prescribing information: Click Here
Get Access To Crenessity (crinecerfont) Capsules In India on request
Brand Name “Crenessity” or Generic Name “crinecerfont” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838
